



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Carboplatin (Standard)

<b>Cat. No.:</b>	HY-17393R
<b>CAS No.:</b>	41575-94-4
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>12</sub> N <sub>2</sub> O <sub>4</sub> Pt
<b>Molecular Weight:</b>	371.25
<b>Target:</b>	Autophagy; DNA/RNA Synthesis; DNA Alkylator/Crosslinker
<b>Pathway:</b>	Autophagy; Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Carboplatin (Standard) is the analytical standard of Carboplatin. This product is intended for research and analytical applications. Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
<b>IC<sub>50</sub> &amp; Target</b>	DNA Alkylator <sup>[1]</sup>

### REFERENCES

- [1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. *Biochem Pharmacol.* 1999 Nov 15;58(10):1625-9.
- [2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. *Cancer Chemother Pharmacol.* 2008 Oct;62(5):769-78.
- [3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. *Mol Cancer Ther.* 2012 Sep;11(9):1948-58.
- [4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. *Genome Med.* 2016 Oct 31;8(1):116.
- [5]. Hall MD, Telma KA, Chang KE, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. *Cancer Res.* 2014;74(14):3913-3922.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA